# Certolizumab in Recurrent Implantation Failure (RIF)

> **NCT05930613** · PHASE3 · RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 161 (estimated)

## Conditions studied

- Recurrent Unexplained Implantation Failure

## Interventions

- **DRUG:** Certolizumab (CIMZIA® ; TNF-α antagonist)
- **DRUG:** Placebo (NaCl 0.9 % solution)

## Key facts

- **NCT ID:** NCT05930613
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-30
- **Primary completion:** 2029-04
- **Final completion:** 2029-04
- **Target enrollment:** 161 (ESTIMATED)
- **Last updated:** 2023-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05930613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05930613, "Certolizumab in Recurrent Implantation Failure (RIF)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05930613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*